Anagha Dhore, Karandikar YS*, Vaibhav Hanumant Khutle, Shreyash Madankar, Nishant Tangadi, Rohan Bhagat
SKN Medical College & General Hospital, Pune, Maharashtra, INDIA
*Address for Corresponding Author
Dr. Karandikar Y. S.
Associate Professor, SKN Medical College & General Hospital,
Pune, Maharashtra. India.
Phone No: +91-9922747908
Background: Indian drug market is flooded with many drug formulations of antisecretory drugs. The volume of prescribing antisecretory drugs has had a substantial impact on prescribing expenditure worldwide. Pharmacoeconomic research focuses on providing quality care within limited financial resources. Objective: The purpose of this study was to perform Pharmacoeconomic evaluation and determine cost saving measures in the treatment of patients with conditions requiring antisecretory medications. Materials and methods: We conducted a prospective observational randomized active control open label study. Cost effectiveness ratio for Ranitidine and Pantoprazole was calculated by dividing the cost of treatment by it’s clinical outcome (FSSG score) . Cost minimization analysis was done with three proton pump inhibitors available in the hospital pharmacy assuming that they have equal efficacy as well as from the patient’s perspective (pocket payments ) in accordance with the cost of PPIs available in market (over the counter). Results: In our Hospital, pantoprazole was the most commonly prescribed drugs. The mean improvement score with pantoprazole was 6.27, while in ranitidine group it was of 1.96. The cost of reducing 1 unit FSSG score per day was Rs.0.12 with Pantoprazole and 0.32 with Ranitidine. Cost minimisation analysis showed that Omeprazole is the most economical treatment among available PPI in hospital pharmacy as well as PPI available in market. Conclusion: Pantoprazole was found to be more cost effective drug than Ranitidine as per the price of drug available in Central Hospital Pharmacy. Amongst all PPI , substitution by Omeprazole would be expected to produce cost savings .
Keywords: Pharmacoeconomic evaluation, Pantoprazole, antisecretory drugs, FSSG score